NOTICE OF INTENT TO AWARD SOLE SOURCE Automated Apheresis Equipment

Summary (Newest Update)

Background The contract is issued by the Robertson Blood Center (RBC) at Carl R. Darnall Army Medical Center (CRDAMC), Fort Hood, Texas, which operates under the regulatory authority of the FDA and AABB to provide life-saving blood products for the Armed Services Blood Program (ASBP). The RBC's mission requires flexibility to collect specific blood components based on rapidly changing inventory needs. Terumo Blood and Cell Technologies (BCT) is the sole source recipient of this contract, located at 10811 W. Collins Ave, Lakewood, Colorado. Work Details The contract involves a one-time purchase of Automated Apheresis Equipment specifically the Trima Accel® system. This system is unique as it can concurrently collect any combination of platelets, plasma, and red blood cells from a single donor in one appointment. Competing systems like Haemonetics NexSys PCS® and Fresenius Kabi Aurora Xi™ are not suitable as they are designed solely for plasma collection and cannot collect platelets or red blood cells. The Trima Accel® system offers operational advantages including procedure times that are up to 40% shorter than comparable devices, enhancing donor satisfaction and throughput. It also ensures standardization and interoperability with other ASBP centers that utilize the Trima® platform. Period of Performance The contract is anticipated to be executed in June 2025. Place of Performance Fort Hood, Texas. Bidder Requirements The award is made on a sole-source basis to Terumo Blood and Cell Technologies due to their unique capability to meet the multi-component collection requirements of RBC. No other vendors were found capable of fulfilling these specific needs. Incumbent Analysis (see Incumbents section for more detail) This opportunity appears to have a confirmed incumbent based on the closely related prior contract W81K0219P0226 awarded to Terumo Bct (value $668,028) for the TRIMA ACCEL RBC/PLATELET/PLASMA. The prior work description aligns with the current sole-source notice for automated apheresis equipment, specifically the Trima Accel® system, indicating continuity in procuring the same multi-component collection capability (red blood cells, platelets, and plasma) for use at the same medical center.